Kura Oncology to Report Second Quarter 2020 Financial Results

Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) is set to release its second quarter 2020 financial results on August 6, 2020, after U.S. markets close. Management will hold a webcast and conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Kura focuses on developing precision medicines for cancer with two promising drug candidates: tipifarnib, which targets HRAS mutant head and neck squamous cell carcinoma, and KO-539, aimed at treating acute myeloid leukemia.

Positive

• Kura has two drug candidates in advanced stages: tipifarnib in a registration-directed trial and KO-539 in Phase 1/2A clinical trial.

Negative

• None.

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2020 financial results after the close of U.S. financial markets on Thursday, August 6, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (866) 278-7953 for domestic callers and (323) 347-3281 for international callers and entering the conference code: 1697775. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective inhibitor of the menin-KMT2A(MLL) protein-protein interaction currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

When will Kura Oncology report its Q2 2020 financial results?

Kura Oncology will report its second quarter 2020 financial results on August 6, 2020.

What is the focus of Kura Oncology's development?

Kura Oncology focuses on the development of precision medicines for cancer treatment.

What are Kura's most advanced drug candidates?

Kura's most advanced drug candidates are tipifarnib for HRAS mutant head and neck cancer and KO-539 for acute myeloid leukemia.

What time is the Kura Oncology conference call on August 6, 2020?

The conference call will be held at 4:30 p.m. ET / 1:30 p.m. PT on August 6, 2020.

How can investors access Kura's conference call?

Investors can access the conference call by dialing (866) 278-7953 for domestic calls or (323) 347-3281 for international calls, using conference code 1697775.